Sign in
BBOT Stock Price, Chart, Stats & News
BridgeBio Oncology Therapeutics Inc.
Save
592.79M
Market cap
–
Current P/E
–
Forward P/E
BBOT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -29.90% |
ROE | -65.52% |
D/E | 0.01x |
Interest coverage ratio | – |
BBOT valuation
P/E | – |
P/S | – |
P/B | 0.67x |
P/CF | -2.91x |
P/FCF | -7.44x |
P/OCF | -2.91x |
PEG | 0.06x |
EV multiple | -7.45x |
About
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology.
Similar securities
Based on sector and market capitalization
Report issue